QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-maintains-buy-on-sensei-biotherapeutics-raises-price-target-to-30

HC Wainwright & Co. analyst Joseph Pantginis maintains Sensei Biotherapeutics (NASDAQ:SNSE) with a Buy and raises the pr...

 sensei-biotherapeutics-to-implement-1-for-20-reverse-stock-split-of-issued-and-outstanding-shares-effective-june-16-2025

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage biotechnology company focused on the discovery and development of ...

 hc-wainwright--co-assumes-sensei-biotherapeutics-at-buy-announces-price-target-of-5

HC Wainwright & Co. analyst Matthew Kelsey assumes Sensei Biotherapeutics (NASDAQ:SNSE) with a Buy rating and announces ...

 sensei-biotherapeutics-q1-eps-027-misses-022-estimate

Sensei Biotherapeutics (NASDAQ:SNSE) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate...

 sensei-biotherapeutics-reports-favorable-initial-clinical-activity-data-for-solnerstotug-in-resistant-tumors

Sensei Biotherapeutics' solnerstotug shows a 14% ORR in PD-(L)1 resistant tumors and remains well tolerated in early trial ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION